Skip to content
10-K

Annual Report

MAZE THERAPEUTICS, INC. MAZE

0001193125-26-122778

← back to feed
Filed
Mar 25, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2025 · Dec 31, 2025 42.98M sh
Shares Diluted FY 2025 · Dec 31, 2024 2.73M sh
Capex FY 2025 · Dec 31, 2025 $794K
Capex FY 2025 · Dec 31, 2024 $1.15M
Operating Cash Flow FY 2025 · Dec 31, 2025 −$111.94M
Operating Cash Flow FY 2025 · Dec 31, 2024 $75.95M
Cash And Equivalents FY 2025 · Dec 31, 2025 $189.25M
Cash And Equivalents FY 2025 · Dec 31, 2024 $196.81M
Stockholders Equity FY 2025 · Dec 31, 2025 $354.97M
Stockholders Equity FY 2025 · Dec 31, 2024 −$311.18M
Current Liabilities FY 2025 · Dec 31, 2025 $22.56M
Current Liabilities FY 2025 · Dec 31, 2024 $20.67M
Total Liabilities FY 2025 · Dec 31, 2025 $42.16M
Total Liabilities FY 2025 · Dec 31, 2024 $43.64M
Current Assets FY 2025 · Dec 31, 2025 $349.72M
Current Assets FY 2025 · Dec 31, 2024 $201.67M
Total Assets FY 2025 · Dec 31, 2025 $397.13M
Total Assets FY 2025 · Dec 31, 2024 $240.54M
Eps Diluted FY 2025 · Dec 31, 2025 −$3.05
Eps Diluted FY 2025 · Dec 31, 2024 $1.25
Eps Basic FY 2025 · Dec 31, 2025 −$3.05
Eps Basic FY 2025 · Dec 31, 2024 $1.42
Sga Expense FY 2025 · Dec 31, 2025 $34.45M
Sga Expense FY 2025 · Dec 31, 2024 $26.42M
Rd Expense FY 2025 · Dec 31, 2025 $108.45M
Rd Expense FY 2025 · Dec 31, 2024 $83.5M
Net Income FY 2025 · Dec 31, 2025 −$131.12M
Net Income FY 2025 · Dec 31, 2024 $52.23M
Operating Income FY 2025 · Dec 31, 2025 −$142.9M
Operating Income FY 2025 · Dec 31, 2024 $57.59M
Revenue FY 2025 · Dec 31, 2024 $167.5M